Abstract
Pharmaceutical care programs may be an option to improve blood pressure (BP) control in patients with uncontrolled hypertension. The aim of this study was to evaluate the efficacy of pharmaceutical care programs in treating patients with resistant hypertension. In a double-blind randomized clinical trial, 71 patients with uncontrolled BP were enrolled in a pharmaceutical care program or in a control group and underwent a series of cognitive tests. The primary outcome was change in ambulatory BP (ABP) between the baseline evaluation and the final visit 6 months later. The secondary outcomes were the frequency of drug-related problems and adherence as determined by plasma levels of hydrochlorothiazide. The delta-values between the intervention and control groups for ABP in the different daily periods, with the corresponding 95% confidence limits, adjusted for age and baseline BP were: 3 (-1 to 5), 2 (-2 to 4), and 5 (-1 to 6) mm Hg for 24 h, daily and nightly systolic BP, respectively. The corresponding values for diastolic BP were 1 (-1 to 3), 0 (-2 to 2), and 3 (-1 to 4) mm Hg, respectively. Hydrochlorothiazide was detected in the plasma in 21 of 27 patients in the intervention group that attended to all appointments and 24 of ...Continue Reading
References
Jan 1, 1989·The International Journal of Social Psychiatry·E Iacoponi, J J Mari
Jun 1, 1994·The Gerontologist·H L Lipton, J A Bird
Jul 1, 1997·Journal of Hypertension·F D FuchsR Machado
May 14, 1999·Journal of the American Geriatrics Society·T von Sternberg
Jul 3, 1999·Journal of Clinical Epidemiology·W D MoreiraL J Appel
Feb 15, 2001·Archives of Internal Medicine·M GusL B Moreira
Feb 28, 2002·Archives of Internal Medicine·Susan A OliveriaSteven M Asch
Dec 11, 2002·JAMA : the Journal of the American Medical Association·Heather P McDonaldR Brian Haynes
Apr 3, 2003·The Journal of Clinical Hypertension·Joel M Neutel, David H G Smith
Oct 28, 2003·Journal of Human Hypertension·F D FuchsG Nunes
Citations
Oct 28, 2009·Archives of Internal Medicine·Barry L CarterPaul A James
Aug 23, 2011·PloS One·Úrsula JacobsMaria Beatriz C Ferreira
Dec 15, 2010·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Liam G GlynnTom Fahey
Jun 2, 2011·International Journal of Hypertension·Dimitrios SyrseloudisChristodoulos Stefanadis
Jul 20, 2012·American Journal of Hypertension·Glaube RiegelFlávio D Fuchs
Jan 12, 2017·Ciência & saúde coletiva·Daniela Oliveira de Melo, Lia Lusitana Cardozo de Castro
Jan 12, 2017·Ciência & saúde coletiva·Daniela Oliveira de MeloNicolina Silvana Romano-Lieber
Aug 2, 2007·The Annals of Pharmacotherapy·Mauro Silveira de Castro, Cassyano Januário Correr
Sep 5, 2018·The Cochrane Database of Systematic Reviews·Mícheál de BarraMargaret C Watson
Apr 12, 2014·Journal of the American Heart Association·Valérie SantschiGilles Paradis
Jan 12, 2007·The Journal of Clinical Hypertension·Jeanie Park, Vito Campese
Apr 26, 2008·Pediatric Transplantation·E ShemeshS Emre
Jan 25, 2011·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Manuel P MorgadoMiguel Castelo-Branco
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Liam G GlynnTom Fahey
Nov 13, 2019·Journal of the American Heart Association·Francisco Martínez-MardonesVictoria Garcia-Cardenas
May 15, 2015·PloS One·Alessandra R MesquitaDivaldo P Lyra Júnior
Feb 19, 2020·Journal of Pharmacy Practice·Landon ReevesGeorges Adunlin
Sep 22, 2010·The Journal of Cardiovascular Nursing·Todd M Ruppar
Mar 12, 2011·International Journal of Clinical Pharmacy·Cassyano Januário CorrerRoberto Pontarolo
Aug 9, 2018·JMIR Research Protocols·Sandra C FuchsFlavio D Fuchs
Apr 18, 2019·Journal of Advanced Nursing·Jinhan Pamala TanRosalind Chiew-Jiat Siah
Mar 8, 2017·The Journal of Clinical Hypertension·Camila G RighiFlavio D Fuchs
Mar 13, 2014·Deutsches Ärzteblatt International·Jan Matthes, Christian Albus
Jan 10, 2012·Research in Social & Administrative Pharmacy : RSAP·Patricia M AguiarDivaldo P Lyra